Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 9.131
1.
Sci Rep ; 14(1): 12981, 2024 06 05.
Article En | MEDLINE | ID: mdl-38839916

Micro RNAs (miRNAs, miRs) and relevant networks might exert crucial functions during differential host cell infection by the different Leishmania species. Thus, a bioinformatic analysis of microarray datasets was developed to identify pivotal shared biomarkers and miRNA-based regulatory networks for Leishmaniasis. A transcriptomic analysis by employing a comprehensive set of gene expression profiling microarrays was conducted to identify the key genes and miRNAs relevant for Leishmania spp. infections. Accordingly, the gene expression profiles of healthy human controls were compared with those of individuals infected with Leishmania mexicana, L. major, L. donovani, and L. braziliensis. The enrichment analysis for datasets was conducted by utilizing EnrichR database, and Protein-Protein Interaction (PPI) network to identify the hub genes. The prognostic value of hub genes was assessed by using receiver operating characteristic (ROC) curves. Finally, the miRNAs that interact with the hub genes were identified using miRTarBase, miRWalk, TargetScan, and miRNet. Differentially expressed genes were identified between the groups compared in this study. These genes were significantly enriched in inflammatory responses, cytokine-mediated signaling pathways and granulocyte and neutrophil chemotaxis responses. The identification of hub genes of recruited datasets suggested that TNF, SOCS3, JUN, TNFAIP3, and CXCL9 may serve as potential infection biomarkers and could deserve value as prognostic biomarkers for leishmaniasis. Additionally, inferred data from miRWalk revealed a significant degree of interaction of a number of miRNAs (hsa-miR-8085, hsa-miR-4673, hsa-miR-4743-3p, hsa-miR-892c-3p, hsa-miR-4644, hsa-miR-671-5p, hsa-miR-7106-5p, hsa-miR-4267, hsa-miR-5196-5p, and hsa-miR-4252) with the majority of the hub genes, suggesting such miRNAs play a crucial role afterwards parasite infection. The hub genes and hub miRNAs identified in this study could be potentially suggested as therapeutic targets or biomarkers for the management of leishmaniasis.


Biomarkers , Computational Biology , Gene Expression Profiling , Gene Regulatory Networks , Leishmaniasis , MicroRNAs , Protein Interaction Maps , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Leishmaniasis/genetics , Leishmaniasis/parasitology , Computational Biology/methods , Biomarkers/metabolism , Gene Expression Profiling/methods , Protein Interaction Maps/genetics , Transcriptome , Leishmania/genetics
2.
BMC Infect Dis ; 24(1): 551, 2024 Jun 01.
Article En | MEDLINE | ID: mdl-38824500

BACKGROUND: Leishmaniasis, an illness caused by protozoa, accounts for a substantial number of human fatalities globally, thereby emerging as one of the most fatal parasitic diseases. The conventional methods employed for detecting the Leishmania parasite through microscopy are not only time-consuming but also susceptible to errors. Therefore, the main objective of this study is to develop a model based on deep learning, a subfield of artificial intelligence, that could facilitate automated diagnosis of leishmaniasis. METHODS: In this research, we introduce LeishFuNet, a deep learning framework designed for detecting Leishmania parasites in microscopic images. To enhance the performance of our model through same-domain transfer learning, we initially train four distinct models: VGG19, ResNet50, MobileNetV2, and DenseNet 169 on a dataset related to another infectious disease, COVID-19. These trained models are then utilized as new pre-trained models and fine-tuned on a set of 292 self-collected high-resolution microscopic images, consisting of 138 positive cases and 154 negative cases. The final prediction is generated through the fusion of information analyzed by these pre-trained models. Grad-CAM, an explainable artificial intelligence technique, is implemented to demonstrate the model's interpretability. RESULTS: The final results of utilizing our model for detecting amastigotes in microscopic images are as follows: accuracy of 98.95 1.4%, specificity of 98 2.67%, sensitivity of 100%, precision of 97.91 2.77%, F1-score of 98.92 1.43%, and Area Under Receiver Operating Characteristic Curve of 99 1.33. CONCLUSION: The newly devised system is precise, swift, user-friendly, and economical, thus indicating the potential of deep learning as a substitute for the prevailing leishmanial diagnostic techniques.


Deep Learning , Leishmania , Leishmaniasis , Microscopy , Telemedicine , Humans , Leishmaniasis/parasitology , Leishmaniasis/diagnosis , Leishmania/isolation & purification , Microscopy/methods , COVID-19 , SARS-CoV-2/isolation & purification
3.
Ugeskr Laeger ; 186(17)2024 Apr 22.
Article Da | MEDLINE | ID: mdl-38704708

Leishmaniasis is transmitted by sandflies and involves cutaneous, mucocutaneous, or visceral disease. Sporadic, imported cases in Denmark emphasize the need for greater awareness. The incidence is stable with at least ten verified cases per year. Diagnostic methods include PCR- and antibody tests with a high positivity rate for PCR (17%) and a low positivity rate for antibody (1.4%). The latter should be used only when visceral disease is suspected. Immunosuppressed patients are at particular risk. Treatment strategies are chosen according to the severity of the condition, as argued in this review.


Leishmaniasis , Humans , Denmark/epidemiology , Leishmaniasis/diagnosis , Communicable Diseases, Imported/diagnosis , Antiprotozoal Agents/therapeutic use , Polymerase Chain Reaction , Leishmaniasis, Cutaneous/diagnosis
4.
PLoS One ; 19(5): e0303686, 2024.
Article En | MEDLINE | ID: mdl-38781128

The intracellular protozoan parasite Leishmania causes leishmaniasis in humans, leading to serious illness and death in tropical and subtropical areas worldwide. Unfortunately, due to the unavailability of approved vaccines for humans and the limited efficacy of available drugs, leishmaniasis is on the rise. A comprehensive understanding of host-pathogen interactions at the molecular level could pave the way to counter leishmaniasis. There is growing evidence that several intracellular pathogens target RNA interference (RNAi) pathways in host cells to facilitate their persistence. The core elements of the RNAi system are complexes of Argonaute (Ago) proteins with small non-coding RNAs, also known as RNA-induced silencing complexes (RISCs). Recently, we have shown that Leishmania modulates Ago1 protein of host macrophages for its survival. In this study, we biochemically characterize the Ago proteins' interactome in Leishmania-infected macrophages compared to non-infected cells. For this, a quantitative proteomic approach using stable isotope labelling by amino acids in cell culture (SILAC) was employed, followed by purification of host Ago-complexes using a short TNRC6 protein-derived peptide fused to glutathione S-transferase beads as an affinity matrix. Proteomic-based detailed biochemical analysis revealed Leishmania modulated host macrophage RISC composition during infection. This analysis identified 51 Ago-interacting proteins with a broad range of biological activities. Strikingly, Leishmania proteins were detected as part of host Ago-containing complexes in infected cells. Our results present the first report of comprehensive quantitative proteomics of Ago-containing complexes isolated from Leishmania-infected macrophages and suggest targeting the effector complex of host RNAi machinery. Additionally, these results expand knowledge of RISC in the context of host-pathogen interactions in parasitology in general.


Argonaute Proteins , Macrophages , Argonaute Proteins/metabolism , Argonaute Proteins/genetics , Humans , Macrophages/parasitology , Macrophages/metabolism , Proteomics/methods , Leishmania/metabolism , RNA Interference , Leishmaniasis/parasitology , Leishmaniasis/metabolism
5.
Vet Rec ; 194(11): e4089, 2024 Jun 01.
Article En | MEDLINE | ID: mdl-38809570

BACKGROUND: This study examined the experiences of owners of dogs with leishmaniosis who treated their dogs with daily subcutaneous meglumine antimoniate injections. The owners' perceived ease of administering the injections, the occurrence of problems and the effects on the owners and on the dog‒owner bond were evaluated. METHODS: Dogs prescribed meglumine antimoniate as a treatment for leishmaniosis were identified using the database of the veterinary pharmacy of the Faculty of Veterinary Medicine, Utrecht University. An online questionnaire was sent to the owners of these dogs to evaluate the perceived ease of administering the injections, the occurrence of problems and the effects on the owner and the dog-owner bond. RESULTS: Responses were received from 64 dog owners. Most respondents (78%) reported that administering the injections was not difficult. Pain or the development of nodules at the injection site was reported in 50% and 40% of the dogs, respectively. Polyuria was reported in 44% of the dogs. Some owners reported that administering the injections had a negative impact on their psychological wellbeing (20%), and some would have liked more veterinary support (11%). LIMITATIONS: Some questions were answered by a limited number of people, and their responses may not be representative. CONCLUSION: Dog owners remain highly motivated to persevere with meglumine antimoniate treatment and are willing to administer the injections themselves. The availability of active support when needed during the therapy cycle may further improve their acceptance of and confidence in giving the injections.


Antiprotozoal Agents , Dog Diseases , Leishmaniasis , Meglumine Antimoniate , Dogs , Animals , Meglumine Antimoniate/therapeutic use , Meglumine Antimoniate/administration & dosage , Dog Diseases/drug therapy , Leishmaniasis/veterinary , Leishmaniasis/drug therapy , Surveys and Questionnaires , Humans , Male , Antiprotozoal Agents/therapeutic use , Antiprotozoal Agents/administration & dosage , Female , Ownership , Meglumine/therapeutic use , Meglumine/administration & dosage , Organometallic Compounds/administration & dosage , Organometallic Compounds/therapeutic use , Injections, Subcutaneous/veterinary
6.
J Med Chem ; 67(10): 8323-8345, 2024 May 23.
Article En | MEDLINE | ID: mdl-38722757

Leishmaniasis is a neglected tropical disease that is estimated to afflict over 12 million people. Current drugs for leishmaniasis suffer from serious deficiencies, including toxicity, high cost, modest efficacy, primarily parenteral delivery, and emergence of widespread resistance. We have discovered and developed a natural product-inspired tambjamine chemotype, known to be effective against Plasmodium spp, as a novel class of antileishmanial agents. Herein, we report in vitro and in vivo antileishmanial activities, detailed structure-activity relationships, and metabolic/pharmacokinetic profiles of a large library of tambjamines. A number of tambjamines exhibited excellent potency against both Leishmania mexicana and Leishmania donovani parasites with good safety and metabolic profiles. Notably, tambjamine 110 offered excellent potency and provided partial protection to leishmania-infected mice at 40 and/or 60 mg/kg/10 days of oral treatment. This study presents the first account of antileishmanial activity in the tambjamine family and paves the way for the generation of new oral antileishmanial drugs.


Antiprotozoal Agents , Leishmania donovani , Leishmania mexicana , Animals , Structure-Activity Relationship , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/chemistry , Antiprotozoal Agents/therapeutic use , Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/pharmacokinetics , Mice , Leishmania donovani/drug effects , Leishmania mexicana/drug effects , Drug Discovery , Humans , Female , Leishmaniasis/drug therapy , Mice, Inbred BALB C
7.
Molecules ; 29(10)2024 May 09.
Article En | MEDLINE | ID: mdl-38792079

Infectious diseases caused by trypanosomatids, including African trypanosomiasis (sleeping sickness), Chagas disease, and different forms of leishmaniasis, are Neglected Tropical Diseases affecting millions of people worldwide, mainly in vulnerable territories of tropical and subtropical areas. In general, current treatments against these diseases are old-fashioned, showing adverse effects and loss of efficacy due to misuse or overuse, thus leading to the emergence of resistance. For these reasons, searching for new antitrypanosomatid drugs has become an urgent necessity, and different metabolic pathways have been studied as potential drug targets against these parasites. Considering that trypanosomatids possess a unique redox pathway based on the trypanothione molecule absent in the mammalian host, the key enzymes involved in trypanothione metabolism, trypanothione reductase and trypanothione synthetase, have been studied in detail as druggable targets. In this review, we summarize some of the recent findings on the molecules inhibiting these two essential enzymes for Trypanosoma and Leishmania viability.


Amide Synthases , Glutathione , NADH, NADPH Oxidoreductases , Trypanosoma , NADH, NADPH Oxidoreductases/metabolism , NADH, NADPH Oxidoreductases/antagonists & inhibitors , Humans , Amide Synthases/metabolism , Amide Synthases/antagonists & inhibitors , Trypanosoma/drug effects , Trypanosoma/metabolism , Glutathione/metabolism , Glutathione/analogs & derivatives , Animals , Spermidine/analogs & derivatives , Spermidine/metabolism , Leishmania/drug effects , Leishmania/metabolism , Trypanocidal Agents/pharmacology , Trypanocidal Agents/therapeutic use , Leishmaniasis/drug therapy , Leishmaniasis/metabolism , Leishmaniasis/parasitology , Trypanosomatina/metabolism , Trypanosomatina/drug effects , Protozoan Proteins/metabolism , Protozoan Proteins/antagonists & inhibitors , Chagas Disease/drug therapy , Chagas Disease/parasitology , Chagas Disease/metabolism
8.
Diagn Microbiol Infect Dis ; 109(3): 116326, 2024 Jul.
Article En | MEDLINE | ID: mdl-38692205

Serodiagnosis methods have been used as platforms for diagnostic tests for many diseases. Due to magnetic nanoparticles' properties to quickly detach from an external magnetic field and particle size effects, these nanomaterials' functionalization allows the specific isolation of target analytes, enhancing accuracy parameters and reducing serodiagnosis time. Superparamagnetic iron oxide nanoparticles (MNPs) were synthesized and functionalized with polyethylene glycol (PEG) and then associated with the synthetic Leishmaniosis epitope. This nano-peptide antigen showed promising results. Regarding Tegumentary leishmaniasis diagnostic accuracy, the AUC was 0.8398 with sensibility 75% (95CI% 50.50 - 89.82) and specificity 87.50% (95CI% 71.93 - 95.03), and Visceral leishmaniasis accuracy study also present high performance, the AUC was 0.9258 with sensibility 87.50% (95CI% 63.98 - 97.78) and specificity 87.50% (95CI% 71.93 - 95.03). Our results demonstrate that the association of the antigen with MNPs accelerates and improves the diagnosis process. MNPs could be an important tool for enhancing serodiagnosis.


Enzyme-Linked Immunosorbent Assay , Polyethylene Glycols , Sensitivity and Specificity , Humans , Enzyme-Linked Immunosorbent Assay/methods , Polyethylene Glycols/chemistry , Antigens, Protozoan/immunology , Leishmaniasis/diagnosis , Magnetic Iron Oxide Nanoparticles/chemistry , Antibodies, Protozoan/blood
9.
Phytomedicine ; 129: 155640, 2024 Jul.
Article En | MEDLINE | ID: mdl-38714091

BACKGROUND: The discovery of artemisinin, an endoperoxide, encouraged the scientific community to explore endoperoxides as potential anti-parasitic molecules. Although artemisinin derivatives are rapidly evolving as potent anti-malarials, their potential as anti-leishmanials is emerging gradually. The treatment of leishmaniasis, a group of neglected tropical diseases is handicapped by lack of effective vaccines, drug toxicities and drug resistance. The weak antioxidant defense mechanism of the Leishmania parasites due to lack of catalase and a selenium dependent glutathione peroxidase system makes them vulnerable to oxidative stress, and this has been successful exploited by endoperoxides. PURPOSE: The study aimed to review the available literature on the anti-leishmanial efficacy of natural endoperoxides with a view to achieve insights into their mode of actions. METHODS: We reviewed more around 110 research and review articles restricted to the English language, sourced from electronic bibliographic databases including PubMed, Google, Web of Science, Google scholar etc. RESULTS: Natural endoperoxides could potentially augment the anti-leishmanial drug library, with artemisinin and ascaridole emerging as potential anti-leishmanial agents. Due to higher reactivity of the cyclic peroxide moiety, and exploiting the compromised antioxidant defense of Leishmania, endoperoxides like artemisinin and ascaridole potentiate their leishmanicidal efficacy by creating a redox imbalance. Furthermore, these molecules minimally impair oxidative phosphorylation; instead inhibit glycolytic functions, culminating in depolarization of the mitochondrial membrane and depletion of ATP. Additionally, the carbon-centered free radicals generated from endoperoxides, participate in chain reactions that can generate even more reactive organic radicals that are toxic to macromolecules, including lipids, proteins and DNA, leading to cell cycle arrest and apoptosis of Leishmania parasites. However, the precise target(s) of the toxic free radicals remains open-ended. CONCLUSION: In this overview, the spectrum of natural endoperoxide molecules as major anti-leishmanials and their mechanism of action has been delineated. In view of the substantial evidence that natural endoperoxides (e.g., artemisinin, ascaridole) exert a noxious effect on different species of Leishmania, identification and characterization of other natural endoperoxides is a promising therapeutic option worthy of further pharmacological consideration.


Antiprotozoal Agents , Artemisinins , Leishmania , Peroxides , Leishmania/drug effects , Peroxides/pharmacology , Peroxides/chemistry , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/chemistry , Artemisinins/pharmacology , Artemisinins/chemistry , Humans , Leishmaniasis/drug therapy , Oxidative Stress/drug effects , Animals , Antioxidants/pharmacology
10.
PLoS Negl Trop Dis ; 18(5): e0011897, 2024 May.
Article En | MEDLINE | ID: mdl-38739677

Leishmania, the dixenous trypanosomatid parasites, are the causative agents of leishmaniasis currently divided into four subgenera: Leishmania, Viannia, Sauroleishmania, and the recently described Mundinia, consisting of six species distributed sporadically all over the world infecting humans and/or animals. These parasites infect various mammalian species and also cause serious human diseases, but their reservoirs are unknown. Thus, adequate laboratory models are needed to enable proper research of Mundinia parasites. In this complex study, we compared experimental infections of five Mundinia species (L. enriettii, L. macropodum, L. chancei, L. orientalis, and four strains of L. martiniquensis) in three rodent species: BALB/c mouse, Chinese hamster (Cricetulus griseus) and steppe lemming (Lagurus lagurus). Culture-derived parasites were inoculated intradermally into the ear pinnae and progress of infection was monitored for 20 weeks, when the tissues and organs of animals were screened for the presence and quantity of Leishmania. Xenodiagnoses with Phlebotomus duboscqi were performed at weeks 5, 10, 15 and 20 post-infection to test the infectiousness of the animals throughout the experiment. BALB/c mice showed no signs of infection and were not infectious to sand flies, while Chinese hamsters and steppe lemmings proved susceptible to all five species of Mundinia tested, showing a wide spectrum of disease signs ranging from asymptomatic to visceral. Mundinia induced significantly higher infection rates in steppe lemmings compared to Chinese hamsters, and consequently steppe lemmings were more infectious to sand flies: In all groups tested, they were infectious from the 5th to the 20th week post infection. In conclusion, we identified two rodent species, Chinese hamster (Cricetulus griseus) and steppe lemming (Lagurus lagurus), as candidates for laboratory models for Mundinia allowing detailed studies of these enigmatic parasites. Furthermore, the long-term survival of all Mundinia species in steppe lemmings and their infectiousness to vectors support the hypothesis that some rodents have the potential to serve as reservoir hosts for Mundinia.


Arvicolinae , Disease Models, Animal , Leishmania , Leishmaniasis , Mice, Inbred BALB C , Animals , Leishmania/classification , Leishmaniasis/parasitology , Mice , Cricetinae , Arvicolinae/parasitology , Cricetulus , Female
11.
Schweiz Arch Tierheilkd ; 166(4): 207-215, 2024 Apr.
Article En | MEDLINE | ID: mdl-38572822

INTRODUCTION: This case report describes the long-term success of a subcutaneous ureteral bypass device in a dog for treatment of a ureteral obstruction. The suspected xanthine urolithiasis was secondary to treatment with allopurinol for leishmaniasis. The dog presented initially with lethargy, anuria and abdominal pain. Mild azotemia was found on biochemical analysis and abdominal ultrasound revealed bilateral ureteral obstruction. A subcutaneous ureteral bypass was subsequently placed using a standard surgical technique. The dog recovered uneventfully and the azotemia resolved within days. Follow-up examinations were performed every trimester for over three years and no complications like obstruction of the bypass tubes, urinary tract infection or azotemia were recognized during this follow-up period. Allopurinol was replaced with domperidone as long-term treatment against Leishmaniasis which resulted in a mild increase of the leishmania serum antibody titer. The subcutaneous ureteral bypass placement was successful and safe in this dog and is a valuable alternative in cases of ureteral obstruction also in dogs.


INTRODUCTION: Ce rapport de cas décrit le succès à long terme d'une dérivation urétérale sous-cutanée chez un chien pour le traitement d'une obstruction urétérale. L'urolithiase xanthique suspectée était secondaire à un traitement à l'allopurinol contre la leishmaniose. Le chien a d'abord présenté une léthargie, une anurie et des douleurs abdominales. L'analyse biochimique a révélé une légère azotémie et l'échographie abdominale a révélé une obstruction urétérale bilatérale. Une dérivation urétérale sous-cutanée a été mise en place selon une technique chirurgicale standard. Le chien s'est rétabli sans incident et l'azotémie a disparu en quelques jours. Des examens de suivi ont été effectués tous les trimestres pendant plus de trois ans et aucune complication telle qu'une obstruction du tube de dérivation, une infection urinaire ou une azotémie n'a été constatée au cours de cette période de suivi. L'allopurinol a été remplacé par de la dompéridone dans le cadre d'un traitement à long terme contre la leishmaniose, ce qui a entraîné une légère augmentation du titre des anticorps sériques contre la leishmaniose. La mise en place d'une dérivation urétérale sous-cutanée s'est avérée efficace et sûre chez ce chien et constitue une alternative intéressante en cas d'obstruction urétérale, y compris chez les chiens.


Azotemia , Cat Diseases , Dog Diseases , Leishmaniasis , Ureteral Obstruction , Urolithiasis , Animals , Dogs , Cats , Ureteral Obstruction/etiology , Ureteral Obstruction/surgery , Ureteral Obstruction/veterinary , Allopurinol/therapeutic use , Azotemia/veterinary , Urolithiasis/surgery , Urolithiasis/veterinary , Leishmaniasis/veterinary , Xanthines , Stents/veterinary , Dog Diseases/drug therapy , Dog Diseases/surgery
12.
Biomolecules ; 14(4)2024 Mar 27.
Article En | MEDLINE | ID: mdl-38672424

Originally developed as a chemotherapeutic agent, miltefosine (hexadecylphosphocholine) is an inhibitor of phosphatidylcholine synthesis with proven antiparasitic effects. It is the only oral drug approved for the treatment of Leishmaniasis and American Trypanosomiasis (Chagas disease). Although its precise mechanisms are not yet fully understood, miltefosine exhibits broad-spectrum anti-parasitic effects primarily by disrupting the intracellular Ca2+ homeostasis of the parasites while sparing the human hosts. In addition to its inhibitory effects on phosphatidylcholine synthesis and cytochrome c oxidase, miltefosine has been found to affect the unique giant mitochondria and the acidocalcisomes of parasites. Both of these crucial organelles are involved in Ca2+ regulation. Furthermore, miltefosine has the ability to activate a specific parasite Ca2+ channel that responds to sphingosine, which is different to its L-type VGCC human ortholog. Here, we aimed to provide an overview of recent advancements of the anti-parasitic mechanisms of miltefosine. We also explored its multiple molecular targets and investigated how its pleiotropic effects translate into a rational therapeutic approach for patients afflicted by Leishmaniasis and American Trypanosomiasis. Notably, miltefosine's therapeutic effect extends beyond its impact on the parasite to also positively affect the host's immune system. These findings enhance our understanding on its multi-targeted mechanism of action. Overall, this review sheds light on the intricate molecular actions of miltefosine, highlighting its potential as a promising therapeutic option against these debilitating parasitic diseases.


Calcium , Chagas Disease , Homeostasis , Leishmaniasis , Phosphorylcholine , Phosphorylcholine/analogs & derivatives , Humans , Phosphorylcholine/pharmacology , Phosphorylcholine/therapeutic use , Chagas Disease/drug therapy , Chagas Disease/parasitology , Chagas Disease/metabolism , Calcium/metabolism , Leishmaniasis/drug therapy , Leishmaniasis/metabolism , Leishmaniasis/parasitology , Homeostasis/drug effects , Animals , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/therapeutic use , Mitochondria/metabolism , Mitochondria/drug effects , Leishmania/drug effects , Leishmania/metabolism , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/metabolism
13.
ACS Infect Dis ; 10(4): 1414-1428, 2024 Apr 12.
Article En | MEDLINE | ID: mdl-38556987

PDZ protein interacting specifically with Tc10 or PIST is a mammalian trans-Golgi resident protein that regulates subcellular sorting of plasma membrane receptors. PIST has recently emerged as a key player in regulating viral pathogenesis. Nevertheless, the involvement of PIST in parasitic infections remains unexplored. Leishmania parasites infiltrate their host macrophage cells through phagocytosis, where they subsequently multiply within the parasitophorous vacuole (PV). Host cell autophagy has been found to be important in regulating this parasite infection. Since PIST plays a pivotal role in triggering autophagy through the Beclin 1-PI3KC3 pathway, it becomes interesting to identify the status of PIST during Leishmania infection. We found that while macrophage cells are infected with Leishmania major (L. major), the expression of PIST protein remains unaltered; however, it traffics from the Golgi compartment to PV. Further, we identified that in L. major-infected macrophage cells, PIST associates with the autophagy regulatory protein Beclin 1 within the PVs; however, PIST does not interact with LC3. Reduction in PIST protein through siRNA silencing significantly increased parasite burden, whereas overexpression of PIST in macrophages restricted L. major infectivity. Together, our study reports that the macrophage PIST protein is essential in regulating L. major infectivity.


Leishmania major , Leishmaniasis , Macrophages , Animals , Beclin-1/metabolism , Carrier Proteins/metabolism , Leishmania major/metabolism , Macrophages/parasitology
14.
Parasit Vectors ; 17(1): 198, 2024 Apr 30.
Article En | MEDLINE | ID: mdl-38689318

Canine leishmaniasis is a widespread disease on the American continent, with cases reported from Uruguay to the USA and Canada. While numerous Leishmania spp. have been reported in dogs in this region, Leishmania infantum and Leishmania braziliensis are the most common etiological agents of canine leishmaniasis from a continental perspective. Nonetheless, other species may predominate locally in some countries. The participation of dogs in the transmission cycle of various Leishmania spp. has long been speculated, but evidence indicates that their role as reservoirs of species other than L. infantum is negligible. Various native wildlife (e.g., small rodents, marsupials, sloths, and monkeys) are, in fact, the primary hosts of Leishmania spp. in the Americas. In this review, an updated list of Leishmania spp. infecting dogs in the Americas is presented, along with their distribution and clinical and zoonotic importance.


Dog Diseases , Leishmaniasis , Zoonoses , Animals , Dogs , Humans , Americas/epidemiology , Disease Reservoirs/parasitology , Disease Reservoirs/veterinary , Dog Diseases/parasitology , Dog Diseases/transmission , Dog Diseases/epidemiology , Leishmania/pathogenicity , Leishmaniasis/epidemiology , Leishmaniasis/transmission , Leishmaniasis/veterinary , Zoonoses/transmission , Zoonoses/parasitology
15.
Eur J Med Chem ; 271: 116396, 2024 May 05.
Article En | MEDLINE | ID: mdl-38643671

Neglected tropical diseases (NTDs) comprise diverse infections with more incidence in tropical/sub-tropical areas. In spite of preventive and therapeutic achievements, NTDs are yet serious threats to the public health. Epidemiological reports of world health organization (WHO) indicate that more than 1.5 billion people are afflicted with at least one NTD type. Among NTDs, leishmaniasis, chagas disease (CD) and human African trypanosomiasis (HAT) result in substantial morbidity and death, particularly within impoverished countries. The statistical facts call for robust efforts to manage the NTDs. Currently, most of the anti-NTD drugs are engaged with drug resistance, lack of efficient vaccines, limited spectrum of pharmacological effect and adverse reactions. To circumvent the issue, numerous scientific efforts have been directed to the synthesis and pharmacological development of chemical compounds as anti-infectious agents. A survey of the anti-NTD agents reveals that the majority of them possess privileged nitrogen, sulfur and oxygen-based heterocyclic structures. In this review, recent achievements in anti-infective small molecules against parasitic NTDs are described, particularly from the SAR (Structure activity relationship) perspective. We also explore current advocating strategies to extend the scope of anti-NTD agents.


Neglected Diseases , Neglected Diseases/drug therapy , Humans , Structure-Activity Relationship , Molecular Structure , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Animals , Chagas Disease/drug therapy , Leishmaniasis/drug therapy , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/chemistry , Antiprotozoal Agents/chemical synthesis , Parasitic Sensitivity Tests , Tropical Medicine
16.
ACS Infect Dis ; 10(5): 1520-1535, 2024 May 10.
Article En | MEDLINE | ID: mdl-38669567

The term "zoonosis" denotes diseases transmissible among vertebrate animals and humans. These diseases constitute a significant public health challenge, comprising 61% of human pathogens and causing an estimated 2.7 million deaths annually. Zoonoses not only affect human health but also impact animal welfare and economic stability, particularly in low- and middle-income nations. Leishmaniasis and schistosomiasis are two important neglected tropical diseases with a high prevalence in tropical and subtropical areas, imposing significant burdens on affected regions. Schistosomiasis, particularly rampant in sub-Saharan Africa, lacks alternative treatments to praziquantel, prompting concerns regarding parasite resistance. Similarly, leishmaniasis poses challenges with unsatisfactory treatments, urging the development of novel therapeutic strategies. Effective prevention demands a One Health approach, integrating diverse disciplines to enhance diagnostics and develop safer drugs. Metalloenzymes, involved in parasite biology and critical in different biological pathways, emerged in the last few years as useful drug targets for the treatment of human diseases. Herein we have reviewed recent reports on the discovery of inhibitors of metalloenzymes associated with zoonotic diseases like histone deacetylases (HDACs), carbonic anhydrase (CA), arginase, and heme-dependent enzymes.


Leishmania , Leishmaniasis , Schistosoma , Schistosomiasis , Zoonoses , Animals , Humans , Leishmaniasis/drug therapy , Leishmaniasis/parasitology , Schistosoma/drug effects , Schistosoma/enzymology , Zoonoses/drug therapy , Schistosomiasis/drug therapy , Leishmania/drug effects , Leishmania/enzymology , Carbonic Anhydrases/metabolism , Histone Deacetylases/metabolism , Enzyme Inhibitors/pharmacology
17.
Am J Trop Med Hyg ; 110(6): 1117-1126, 2024 Jun 05.
Article En | MEDLINE | ID: mdl-38593793

Leishmaniasis is considered one of the neglected tropical diseases in the world. Although Bhutan is a member of the visceral leishmaniasis elimination consortium in South Asia, not much attention has been accorded to the disease because of its low incidence. The vector that transmits Leishmania remains poorly understood. In this backdrop, sand-fly surveys were regularly conducted at multiple sites where leishmaniasis cases have been reported in Bhutan. Collections were made using CDC light traps and cattle-baited net traps in 15 villages from February 2019 to May 2022. Six species of Phlebotomus and four species of Sergentomyia were identified from these sites that included two Phlebotomus and three Sergentomyia species discovered for the first time in Bhutan. Sand-fly density varied significantly from village to village, and it showed strong seasonality with peak numbers collected from June to October and almost zero from December to February. Overall, sand-fly density was highest in the basements of the houses and were higher outdoors than indoors. Cattle-baited net traps collected few sand flies during the surveillance period. This work constituted the first systematic sand-fly population surveillance conducted in Bhutan and will provide a baseline for future vector ecology and Leishmania epidemiological studies.


Insect Vectors , Phlebotomus , Psychodidae , Seasons , Animals , Bhutan/epidemiology , Phlebotomus/physiology , Phlebotomus/classification , Insect Vectors/physiology , Insect Vectors/classification , Psychodidae/classification , Psychodidae/physiology , Leishmaniasis/transmission , Leishmaniasis/epidemiology , Cattle , Humans , Female , Animal Distribution , Leishmaniasis, Visceral/epidemiology , Leishmaniasis, Visceral/transmission
18.
Cell Immunol ; 399-400: 104826, 2024.
Article En | MEDLINE | ID: mdl-38669897

Infectious diseases like leishmaniasis, malaria, HIV, tuberculosis, leprosy and filariasis are responsible for an immense burden on public health systems. Among these, leishmaniasis is under the category I diseases as it is selected by WHO (World Health Organization) on the ground of diversity and complexity. High cost, resistance and toxic effects of Leishmania traditional drugs entail identification and development of therapeutic alternative. Since the natural infection elicits robust immunity, consistence efforts are going on to develop a successful vaccine. Clinical trials have been conducted on vaccines like Leish-F1, F2, and F3 formulated using specific Leishmania antigen epitopes. Current strategies utilize individual or combined antigens from the parasite or its insect vector's salivary gland extract, with or without adjuvant formulation for enhanced efficacy. Promising animal data supports multiple vaccine candidates (Lmcen-/-, LmexCen-/-), with some already in or heading for clinical trials. The crucial challenge in Leishmania vaccine development is to translate the research knowledge into affordable and accessible control tools that refines the outcome for those who are susceptible to infection. This review focuses on recent findings in Leishmania vaccines and highlights difficulties facing vaccine development and implementation.


Leishmania , Leishmaniasis Vaccines , Leishmaniasis , Vaccine Development , Humans , Leishmaniasis Vaccines/immunology , Animals , Leishmania/immunology , Leishmaniasis/immunology , Leishmaniasis/prevention & control , Vaccine Development/methods , Antigens, Protozoan/immunology , Clinical Trials as Topic
19.
Internet resource Es | LIS | ID: lis-49585

Ente adscrito al Ministerio del Poder Popular para la Salud cuya misión es desarrollar investigaciones en las diversas ramas de las ciencias biomédicas, ambientales y socioantropológicas de las enfermedades tropicales y sus consecuencias, para la producción de conocimientos, desarrollo de tecnologías y prácticas culturalmente aceptadas, prevención y control de enfermedades endémicas, así como la formación de recursos humanos bajo los principios de universalidad, equidad, solidaridad y respeto a la biodiversidad cultural y ambiental, con capacidad de elevar la calidad de vida de la población de la región sur del país, especialmente de las poblaciones indígenas


Tropical Medicine , Vector Borne Diseases , Endemic Diseases , Malaria , Leishmaniasis , Onchocerciasis , Parasitic Diseases
...